肺炎球菌ワクチン市場。世界の産業動向、シェア、サイズ、成長、機会、および2021-2026年の予測Pneumococcal Vaccine Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026 The global pneumococcal vaccine market grew at a CAGR of around 5% during 2015 & 2020. Pneumococcal disease is caused by Streptococcus pneumoniae bacterium that can lead to severe infection of the ... もっと見る
サマリーThe global pneumococcal vaccine market grew at a CAGR of around 5% during 2015 & 2020. Pneumococcal disease is caused by Streptococcus pneumoniae bacterium that can lead to severe infection of the lungs (pneumonia) and blood (bacteremia) or the lining of the brain and spinal cord (meningitis). The vaccines help protect both children and adults by stimulating the immune system and protecting against the bacterial strains responsible for severe infections. As these vaccines help prevent infection from spreading, reduce fatality rate and eliminate the need for hospitalization, they are widely being used across the globe.According to the World Health Organization (WHO), children under 2-5 years of age are at a high risk of developing pneumococcal disease. This, in confluence with the escalating number of birth rates and the growing concerns among parents about the health of their children, represents one of the major factors bolstering the market growth. Additionally, the increasing geriatric population is contributing to the market growth. This can also be accredited to the contagiousness of the disease, which can cause severe complications in older adults. Furthermore, the rising number of smokers and individuals living with chronic health conditions is positively influencing the market growth. Moreover, the introduction of the Pneumococcal Conjugate Vaccine (PCV) in infant routine immunization by governing agencies of numerous countries is anticipated to propel the market growth. Apart from this, the growing cases of the coronavirus disease (COVID-19) have promoted the utilization of pneumococcal vaccines as a preventative measure against the increased risk of lung infections caused by the viral disease. Looking forward, IMARC Group expects the global pneumococcal vaccine market to exhibit moderate growth during the next five years. Key Market Segmentation: IMARC Group provides an analysis of the key trends in each sub-segment of the global pneumococcal vaccine market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, vaccine type, product type, distribution channel and end user. Breakup by Vaccine Type: Pneumococcal Conjugate Vaccine Pneumococcal Polysaccharide Vaccine Breakup by Product Type: Prevnar 13 Synflorix Pneumovax 23 Breakup by Distribution Channel: Distribution Partner Companies Non-Governmental Organizations (NGO) Government Authorities Breakup by End User: Pediatrics Adults Breakup by Region: North America United States Canada Asia-Pacific China Japan India South Korea Australia Indonesia Others Europe Germany France United Kingdom Italy Spain Russia Others Latin America Brazil Mexico Others Middle East and Africa Competitive Landscape: The competitive landscape of the industry has also been examined along with the profiles of the key players being Astellas Pharma Inc., GlaxoSmithKline Plc., Merck & Co. Inc., Panacea Biotec Ltd., Pfizer Inc., Sanofi S.A., Serum Institute of India Pvt Ltd and Walvax Biotechnology Co. Ltd. Key Questions Answered in This Report: How has the global pneumococcal vaccine market performed so far and how will it perform in the coming years? What has been the impact of COVID-19 on the global pneumococcal vaccine market? What are the key regional markets? What is the breakup of the market based on the vaccine type? What is the breakup of the market based on the product type? What is the breakup of the market based on the distribution channel? What is the breakup of the market based on the end user? What are the various stages in the value chain of the industry? What are the key driving factors and challenges in the industry? What is the structure of the global pneumococcal vaccine market and who are the key players? What is the degree of competition in the industry? 目次1 Preface2 Scope and Methodology 2.1 Objectives of the Study 2.2 Stakeholders 2.3 Data Sources 2.3.1 Primary Sources 2.3.2 Secondary Sources 2.4 Market Estimation 2.4.1 Bottom-Up Approach 2.4.2 Top-Down Approach 2.5 Forecasting Methodology 3 Executive Summary 4 Introduction 4.1 Overview 4.2 Key Industry Trends 5 Global Pneumococcal Vaccine Market 5.1 Market Overview 5.2 Market Performance 5.3 Impact of COVID-19 5.4 Market Forecast 6 Market Breakup by Vaccine Type 6.1 Pneumococcal Conjugate Vaccine 6.1.1 Market Trends 6.1.2 Market Forecast 6.2 Pneumococcal Polysaccharide Vaccine 6.2.1 Market Trends 6.2.2 Market Forecast 7 Market Breakup by Product Type 7.1 Prevnar 13 7.1.1 Market Trends 7.1.2 Market Forecast 7.2 Synflorix 7.2.1 Market Trends 7.2.2 Market Forecast 7.3 Pneumovax 23 7.3.1 Market Trends 7.3.2 Market Forecast 8 Market Breakup by Distribution Channel 8.1 Distribution Partner Companies 8.1.1 Market Trends 8.1.2 Market Forecast 8.2 Non-Governmental Organizations (NGO) 8.2.1 Market Trends 8.2.2 Market Forecast 8.3 Government Authorities 8.3.1 Market Trends 8.3.2 Market Forecast 9 Market Breakup by End User 9.1 Pediatrics 9.1.1 Market Trends 9.1.2 Market Forecast 9.2 Adults 9.2.1 Market Trends 9.2.2 Market Forecast 10 Market Breakup by Region 10.1 North America 10.1.1 United States 10.1.1.1 Market Trends 10.1.1.2 Market Forecast 10.1.2 Canada 10.1.2.1 Market Trends 10.1.2.2 Market Forecast 10.2 Asia-Pacific 10.2.1 China 10.2.1.1 Market Trends 10.2.1.2 Market Forecast 10.2.2 Japan 10.2.2.1 Market Trends 10.2.2.2 Market Forecast 10.2.3 India 10.2.3.1 Market Trends 10.2.3.2 Market Forecast 10.2.4 South Korea 10.2.4.1 Market Trends 10.2.4.2 Market Forecast 10.2.5 Australia 10.2.5.1 Market Trends 10.2.5.2 Market Forecast 10.2.6 Indonesia 10.2.6.1 Market Trends 10.2.6.2 Market Forecast 10.2.7 Others 10.2.7.1 Market Trends 10.2.7.2 Market Forecast 10.3 Europe 10.3.1 Germany 10.3.1.1 Market Trends 10.3.1.2 Market Forecast 10.3.2 France 10.3.2.1 Market Trends 10.3.2.2 Market Forecast 10.3.3 United Kingdom 10.3.3.1 Market Trends 10.3.3.2 Market Forecast 10.3.4 Italy 10.3.4.1 Market Trends 10.3.4.2 Market Forecast 10.3.5 Spain 10.3.5.1 Market Trends 10.3.5.2 Market Forecast 10.3.6 Russia 10.3.6.1 Market Trends 10.3.6.2 Market Forecast 10.3.7 Others 10.3.7.1 Market Trends 10.3.7.2 Market Forecast 10.4 Latin America 10.4.1 Brazil 10.4.1.1 Market Trends 10.4.1.2 Market Forecast 10.4.2 Mexico 10.4.2.1 Market Trends 10.4.2.2 Market Forecast 10.4.3 Others 10.4.3.1 Market Trends 10.4.3.2 Market Forecast 10.5 Middle East and Africa 10.5.1 Market Trends 10.5.2 Market Breakup by Country 10.5.3 Market Forecast 11 SWOT Analysis 11.1 Overview 11.2 Strengths 11.3 Weaknesses 11.4 Opportunities 11.5 Threats 12 Value Chain Analysis 13 Porters Five Forces Analysis 13.1 Overview 13.2 Bargaining Power of Buyers 13.3 Bargaining Power of Suppliers 13.4 Degree of Competition 13.5 Threat of New Entrants 13.6 Threat of Substitutes 14 Price Analysis 15 Competitive Landscape 15.1 Market Structure 15.2 Key Players 15.3 Profiles of Key Players 15.3.1 Astellas Pharma Inc. 15.3.1.1 Company Overview 15.3.1.2 Product Portfolio 15.3.1.3 Financials 15.3.1.4 SWOT Analysis 15.3.2 GlaxoSmithKline Plc. 15.3.2.1 Company Overview 15.3.2.2 Product Portfolio 15.3.2.3 Financials 15.3.2.4 SWOT Analysis 15.3.3 Merck & Co. Inc. 15.3.3.1 Company Overview 15.3.3.2 Product Portfolio 15.3.3.3 Financials 15.3.3.4 SWOT Analysis 15.3.4 Panacea Biotec Ltd. 15.3.4.1 Company Overview 15.3.4.2 Product Portfolio 15.3.4.3 Financials 15.3.4.4 SWOT Analysis 15.3.5 Pfizer Inc. 15.3.5.1 Company Overview 15.3.5.2 Product Portfolio 15.3.5.3 Financials 15.3.5.4 SWOT Analysis 15.3.6 Sanofi S.A. 15.3.6.1 Company Overview 15.3.6.2 Product Portfolio 15.3.6.3 Financials 15.3.6.4 SWOT Analysis 15.3.7 Serum Institute of India Pvt Ltd. 15.3.7.1 Company Overview 15.3.7.2 Product Portfolio 15.3.8 Walvax Biotechnology Co. Ltd. 15.3.8.1 Company Overview 15.3.8.2 Product Portfolio 15.3.8.3 Financials
SummaryThe global pneumococcal vaccine market grew at a CAGR of around 5% during 2015 & 2020. Pneumococcal disease is caused by Streptococcus pneumoniae bacterium that can lead to severe infection of the lungs (pneumonia) and blood (bacteremia) or the lining of the brain and spinal cord (meningitis). The vaccines help protect both children and adults by stimulating the immune system and protecting against the bacterial strains responsible for severe infections. As these vaccines help prevent infection from spreading, reduce fatality rate and eliminate the need for hospitalization, they are widely being used across the globe.According to the World Health Organization (WHO), children under 2-5 years of age are at a high risk of developing pneumococcal disease. This, in confluence with the escalating number of birth rates and the growing concerns among parents about the health of their children, represents one of the major factors bolstering the market growth. Additionally, the increasing geriatric population is contributing to the market growth. This can also be accredited to the contagiousness of the disease, which can cause severe complications in older adults. Furthermore, the rising number of smokers and individuals living with chronic health conditions is positively influencing the market growth. Moreover, the introduction of the Pneumococcal Conjugate Vaccine (PCV) in infant routine immunization by governing agencies of numerous countries is anticipated to propel the market growth. Apart from this, the growing cases of the coronavirus disease (COVID-19) have promoted the utilization of pneumococcal vaccines as a preventative measure against the increased risk of lung infections caused by the viral disease. Looking forward, IMARC Group expects the global pneumococcal vaccine market to exhibit moderate growth during the next five years. Key Market Segmentation: IMARC Group provides an analysis of the key trends in each sub-segment of the global pneumococcal vaccine market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, vaccine type, product type, distribution channel and end user. Breakup by Vaccine Type: Pneumococcal Conjugate Vaccine Pneumococcal Polysaccharide Vaccine Breakup by Product Type: Prevnar 13 Synflorix Pneumovax 23 Breakup by Distribution Channel: Distribution Partner Companies Non-Governmental Organizations (NGO) Government Authorities Breakup by End User: Pediatrics Adults Breakup by Region: North America United States Canada Asia-Pacific China Japan India South Korea Australia Indonesia Others Europe Germany France United Kingdom Italy Spain Russia Others Latin America Brazil Mexico Others Middle East and Africa Competitive Landscape: The competitive landscape of the industry has also been examined along with the profiles of the key players being Astellas Pharma Inc., GlaxoSmithKline Plc., Merck & Co. Inc., Panacea Biotec Ltd., Pfizer Inc., Sanofi S.A., Serum Institute of India Pvt Ltd and Walvax Biotechnology Co. Ltd. Key Questions Answered in This Report: How has the global pneumococcal vaccine market performed so far and how will it perform in the coming years? What has been the impact of COVID-19 on the global pneumococcal vaccine market? What are the key regional markets? What is the breakup of the market based on the vaccine type? What is the breakup of the market based on the product type? What is the breakup of the market based on the distribution channel? What is the breakup of the market based on the end user? What are the various stages in the value chain of the industry? What are the key driving factors and challenges in the industry? What is the structure of the global pneumococcal vaccine market and who are the key players? What is the degree of competition in the industry? Table of Contents1 Preface2 Scope and Methodology 2.1 Objectives of the Study 2.2 Stakeholders 2.3 Data Sources 2.3.1 Primary Sources 2.3.2 Secondary Sources 2.4 Market Estimation 2.4.1 Bottom-Up Approach 2.4.2 Top-Down Approach 2.5 Forecasting Methodology 3 Executive Summary 4 Introduction 4.1 Overview 4.2 Key Industry Trends 5 Global Pneumococcal Vaccine Market 5.1 Market Overview 5.2 Market Performance 5.3 Impact of COVID-19 5.4 Market Forecast 6 Market Breakup by Vaccine Type 6.1 Pneumococcal Conjugate Vaccine 6.1.1 Market Trends 6.1.2 Market Forecast 6.2 Pneumococcal Polysaccharide Vaccine 6.2.1 Market Trends 6.2.2 Market Forecast 7 Market Breakup by Product Type 7.1 Prevnar 13 7.1.1 Market Trends 7.1.2 Market Forecast 7.2 Synflorix 7.2.1 Market Trends 7.2.2 Market Forecast 7.3 Pneumovax 23 7.3.1 Market Trends 7.3.2 Market Forecast 8 Market Breakup by Distribution Channel 8.1 Distribution Partner Companies 8.1.1 Market Trends 8.1.2 Market Forecast 8.2 Non-Governmental Organizations (NGO) 8.2.1 Market Trends 8.2.2 Market Forecast 8.3 Government Authorities 8.3.1 Market Trends 8.3.2 Market Forecast 9 Market Breakup by End User 9.1 Pediatrics 9.1.1 Market Trends 9.1.2 Market Forecast 9.2 Adults 9.2.1 Market Trends 9.2.2 Market Forecast 10 Market Breakup by Region 10.1 North America 10.1.1 United States 10.1.1.1 Market Trends 10.1.1.2 Market Forecast 10.1.2 Canada 10.1.2.1 Market Trends 10.1.2.2 Market Forecast 10.2 Asia-Pacific 10.2.1 China 10.2.1.1 Market Trends 10.2.1.2 Market Forecast 10.2.2 Japan 10.2.2.1 Market Trends 10.2.2.2 Market Forecast 10.2.3 India 10.2.3.1 Market Trends 10.2.3.2 Market Forecast 10.2.4 South Korea 10.2.4.1 Market Trends 10.2.4.2 Market Forecast 10.2.5 Australia 10.2.5.1 Market Trends 10.2.5.2 Market Forecast 10.2.6 Indonesia 10.2.6.1 Market Trends 10.2.6.2 Market Forecast 10.2.7 Others 10.2.7.1 Market Trends 10.2.7.2 Market Forecast 10.3 Europe 10.3.1 Germany 10.3.1.1 Market Trends 10.3.1.2 Market Forecast 10.3.2 France 10.3.2.1 Market Trends 10.3.2.2 Market Forecast 10.3.3 United Kingdom 10.3.3.1 Market Trends 10.3.3.2 Market Forecast 10.3.4 Italy 10.3.4.1 Market Trends 10.3.4.2 Market Forecast 10.3.5 Spain 10.3.5.1 Market Trends 10.3.5.2 Market Forecast 10.3.6 Russia 10.3.6.1 Market Trends 10.3.6.2 Market Forecast 10.3.7 Others 10.3.7.1 Market Trends 10.3.7.2 Market Forecast 10.4 Latin America 10.4.1 Brazil 10.4.1.1 Market Trends 10.4.1.2 Market Forecast 10.4.2 Mexico 10.4.2.1 Market Trends 10.4.2.2 Market Forecast 10.4.3 Others 10.4.3.1 Market Trends 10.4.3.2 Market Forecast 10.5 Middle East and Africa 10.5.1 Market Trends 10.5.2 Market Breakup by Country 10.5.3 Market Forecast 11 SWOT Analysis 11.1 Overview 11.2 Strengths 11.3 Weaknesses 11.4 Opportunities 11.5 Threats 12 Value Chain Analysis 13 Porters Five Forces Analysis 13.1 Overview 13.2 Bargaining Power of Buyers 13.3 Bargaining Power of Suppliers 13.4 Degree of Competition 13.5 Threat of New Entrants 13.6 Threat of Substitutes 14 Price Analysis 15 Competitive Landscape 15.1 Market Structure 15.2 Key Players 15.3 Profiles of Key Players 15.3.1 Astellas Pharma Inc. 15.3.1.1 Company Overview 15.3.1.2 Product Portfolio 15.3.1.3 Financials 15.3.1.4 SWOT Analysis 15.3.2 GlaxoSmithKline Plc. 15.3.2.1 Company Overview 15.3.2.2 Product Portfolio 15.3.2.3 Financials 15.3.2.4 SWOT Analysis 15.3.3 Merck & Co. Inc. 15.3.3.1 Company Overview 15.3.3.2 Product Portfolio 15.3.3.3 Financials 15.3.3.4 SWOT Analysis 15.3.4 Panacea Biotec Ltd. 15.3.4.1 Company Overview 15.3.4.2 Product Portfolio 15.3.4.3 Financials 15.3.4.4 SWOT Analysis 15.3.5 Pfizer Inc. 15.3.5.1 Company Overview 15.3.5.2 Product Portfolio 15.3.5.3 Financials 15.3.5.4 SWOT Analysis 15.3.6 Sanofi S.A. 15.3.6.1 Company Overview 15.3.6.2 Product Portfolio 15.3.6.3 Financials 15.3.6.4 SWOT Analysis 15.3.7 Serum Institute of India Pvt Ltd. 15.3.7.1 Company Overview 15.3.7.2 Product Portfolio 15.3.8 Walvax Biotechnology Co. Ltd. 15.3.8.1 Company Overview 15.3.8.2 Product Portfolio 15.3.8.3 Financials
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(産業機械)の最新刊レポート
IMARC Services Private Limited.社のその他分野での最新刊レポート
本レポートと同じKEY WORD(vaccine)の最新刊レポート
よくあるご質問IMARC Services Private Limited.社はどのような調査会社ですか?インドに調査拠点を持つ調査会社。幅広い分野をカバーしていますがケミカルに特に焦点を当てています。 もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/11/22 10:26 155.52 円 163.34 円 198.56 円 |